Select Medical Holdings Corporation

Select Medical Holdings Corporation (SEM) Market Cap

Select Medical Holdings Corporation has a market capitalization of $2.04B.

Financials based on reported quarter end 2025-12-31

Price: $16.43

0.01 (0.09%)

Market Cap: 2.04B

NYSE · time unavailable

CEO: Thomas Mullin

Sector: Healthcare

Industry: Medical - Care Facilities

IPO Date: 2009-09-25

Website: https://www.selectmedical.com

Select Medical Holdings Corporation (SEM) - Company Information

Market Cap: 2.04B · Sector: Healthcare

Select Medical Holdings Corporation, through its subsidiaries, operates critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. The company's Critical Illness Recovery Hospital segment consists of hospitals that provide services for heart failure, infectious disease, respiratory failure and pulmonary disease, surgery requiring prolonged recovery, renal disease, neurological events, and trauma. Its Rehabilitation Hospital segment offers therapy and rehabilitation treatments, including rehabilitative services for brain and spinal cord injuries, strokes, amputations, neurological disorders, orthopedic conditions, pediatric congenital or acquired disabilities, and cancer. The company's Outpatient Rehabilitation segment operates rehabilitation clinics that provide physical, occupational, and speech rehabilitation programs and services; and specialized programs, such as functional programs for work related injuries, hand therapy, post-concussion rehabilitation, pediatric and cancer rehabilitation, and athletic training services. Its Concentra segment operates and provides occupational health centers and contract services at employer worksites that deliver occupational medicine, consumer health, physical therapy, and wellness services. As of December 31, 2021, the company operated 104 critical illness recovery hospitals in 28 states; 30 rehabilitation hospitals in 12 states; 1,881 outpatient rehabilitation clinics in 38 states and the District of Columbia; and 518 occupational health centers in 41 states, and 134 onsite clinics at employer worksites states. Select Medical Holdings Corporation was founded in 1996 and is headquartered in Mechanicsburg, Pennsylvania.

Analyst Sentiment

60%
Buy

Based on 13 ratings

Analyst 1Y Forecast: $17.50

Average target (based on 2 sources)

Consensus Price Target

Low

$17

Median

$18

High

$19

Average

$18

Potential Upside: 9.6%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 SELECT MEDICAL HOLDINGS CORP (SEM) — Investment Overview

🧩 Business Model Overview

Select Medical Holdings Corporation (NYSE: SEM) operates a diversified platform in the post-acute care segment of the U.S. healthcare system. The company specializes in critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and provides specialty outpatient care, specifically addressing the continuum between acute hospital settings and home-based care. Through its subsidiaries and joint ventures, Select Medical is structured to deliver care via a network spanning across several states, providing specialized expertise in long-term acute care (LTAC), inpatient rehabilitation, and outpatient physical therapy. The company’s model focuses on bridging essential gaps left by traditional acute-care providers, improving patient outcomes through evidence-based practices, and operating as a key intermediary between hospital discharge and full patient recovery. This integrated approach allows Select Medical to cater to complex, high-acuity needs with a tailored operational structure, often working in alignment with larger hospital systems and physician groups.

💰 Revenue Streams & Monetisation Model

Select Medical generates revenue from multiple sources within healthcare services: - Critical Illness Recovery Hospitals (Long-Term Acute Care Hospitals - LTACHs): These hospitals serve patients who are medically complex, often with extended hospital stays and require intensive, specialized equipment or therapies. - Inpatient Rehabilitation Hospitals (IRFs): Facilities focused on physical, occupational, and speech therapy for patients recovering from traumatic illnesses or injuries. - Outpatient Rehabilitation Clinics: Through a broad network of branded outpatient clinics (including brands such as NovaCare and Kessler), Select Medical provides physical therapy, occupational therapy, sports medicine, and related services. - Occupational Health Centers: Select Medical also operates work health clinics under the Concentra brand, offering workplace injury care, physical exams, wellness programs, and other occupational health services. Monetisation primarily arises from a blended model of service-based billing. Payers include Medicare, Medicaid, commercial insurance, workers’ compensation, and direct employer contracts. The company’s diversified payer mix provides a cushion against major reimbursement changes affecting single payer classes.

🧠 Competitive Advantages & Market Positioning

Select Medical distinguishes itself through several key competitive strengths: - Scale and Network Density: With one of the largest portfolios of LTACHs, IRFs, and outpatient clinics in the U.S., Select Medical enjoys operational leverage and broad referral networks. - Partnerships and Joint Ventures: The company maintains strategic alliances with leading health systems (such as Cleveland Clinic and Emory Healthcare), gaining both credibility and a steady pipeline of patient referrals while expanding geographic reach without incurring full capital risk. - Clinical Expertise and Brand Equity: Legacy brand names and clinical track records attract referrals, particularly in medical rehabilitation fields. In some metro areas, Select Medical operates under brands with deep roots and physician trust. - Diversified Service Lines: Exposure across rehabilitation, acute care, and occupational health blunts the impact of cyclical or regulatory pressures on any single business unit.

🚀 Multi-Year Growth Drivers

Several secular factors underpin Select Medical’s long-term growth outlook: - Aging U.S. Population: Demographic trends point to sustained demand for post-acute and rehabilitation services as the population over age 65 grows, driving medical complexity and the need for rehabilitation following acute hospitalizations. - Shift to Value-Based Care: Hospitals and payers increasingly seek post-acute partners capable of demonstrating superior outcomes and lower readmission rates, which favors scalable, data-driven platforms like Select Medical. - Healthcare System Partnerships: Ongoing trend toward health system consolidation and integration creates opportunities for new joint ventures and expanded hospital networks targeting specialty post-acute care. - Expanding Outpatient Physical Therapy: Heightened awareness of musculoskeletal health and preventive care increases the addressable market, aided by strategic clinic openings and tuck-in acquisitions. - Operational Efficiency Initiatives: Technology adoption, telemedicine rollouts, and data analytics are expected to further enhance patient throughput and profitability, especially as labor costs and reimbursement pressures remain top-of-mind.

⚠ Risk Factors to Monitor

Investors should monitor several notable risk areas: - Regulatory and Reimbursement Exposure: As a Medicare/Medicaid-dependent provider, Select Medical faces perennial risk from policy changes affecting reimbursement rates, admission criteria, or length-of-stay guidelines. - Labor Market Constraints: Persistent nursing and therapist shortages could pressure margins or constrain capacity, especially for high-acuity clinical programs. - Competition and Referral Patterns: Market share battles remain intense among post-acute providers, private equity-backed competitors, and not-for-profit health systems building their own capabilities. - Joint Venture Complexity: While JV structures support growth, they introduce potential governance conflicts, performance variability, and integration risks. - Litigation and Professional Liability: As is typical in healthcare, the company faces ongoing exposure to malpractice and regulatory enforcement actions, requiring robust compliance and legal risk management.

📊 Valuation & Market View

Select Medical is typically valued as a diversified healthcare services company. Relative to peers in both acute and post-acute care, SEM tends to trade at a lower earnings multiple due to perceived exposure to regulatory risks, but this is offset by the resilient, cash-generative nature of its multi-segment model. Key valuation drivers include normalized EBITDA margins, consistency of organic volume growth, the quality and stability of joint venture revenues, as well as free cash flow conversion. Capital allocation priorities tend to balance new unit development, opportunistic M&A, and prudent leverage management, supporting a moderate risk profile. Sell-side and market consensus often recognize SEM’s defensive positioning in recessionary environments and demographic-driven demand, while debates tend to center around regulatory uncertainty and competition from health systems vertically integrating their own post-acute services.

🔍 Investment Takeaway

Select Medical Holdings offers exposure to long-term growth in post-acute and rehabilitation healthcare, underpinned by favorable demographic trends and healthcare system transformation. The company’s diversified portfolio, emphasis on scale and partnerships, and multi-channel revenue model provide resilience amidst cyclical and regulatory uncertainties. While reimbursement and labor cost challenges remain salient risks, Select Medical’s strategic focus on operational efficiency, joint ventures, and selective expansion position it as a sustainable operator in a structurally growing sector. More broadly, SEM represents an opportunity for investors seeking to participate in the evolution of healthcare delivery—especially as the system orients toward value-based care—through a platform with demonstrated scale, stable cash flows, and potential for above-market growth over a multi-year horizon.

⚠ AI-generated — informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"SEM’s latest quarter (2025-12-31) reported Revenue of 1.40B and Net Income of 20.2M (EPS: 0.18). YoY, Revenue improved from -122.6M (2024-12-31) to +1.40B, and Net Income moved from -16.1M to +20.2M (an improvement of roughly 226%). QoQ, Revenue rose modestly (+2.4% vs. 2025-09-30), but profitability weakened: Net Income fell from 28.8M to 20.2M (about -30.0% QoQ), with net margin contracting from ~2.11% to ~1.44%. Over the last four quarters, EPS increased through mid-2025 (0.44 in 2025-03-31), then reversed to 0.18 in the most recent quarter. Cash flow detail isn’t provided, but balance sheet trends suggest increased financial risk: Total Assets increased ~4% YoY, while Net Debt worsened materially (3.68B vs. 2.64B at 2024-12-31) and also surged QoQ (from 0.97B to 3.68B). Shareholder returns have been muted—1Y price change is only +0.37%, and the dividend yield is ~0.42% (limited contribution to total return). With a consensus price target of 18 vs. 16.39, valuation upside appears moderate (~10%)."

Revenue Growth

Neutral

Latest revenue was up QoQ (+2.4%), and YoY revenue swung from negative in 2024-12-31 to positive in 2025-12-31 (approx. +1,239% on an absolute basis). Near-term growth is modest.

Profitability

Caution

Net income declined QoQ (28.8M to 20.2M, ~-30.0%) and net margin contracted (~2.11% to ~1.44%). YoY profitability improved from loss to profit, but the most recent quarter shows deterioration.

Cash Flow Quality

Fair

No operating cash flow data provided, so cash generation quality can’t be directly verified. Dividend payout ratio is elevated in latest quarter (~38%), suggesting caution but not immediate distress.

Leverage & Balance Sheet

Neutral

Equity is relatively stable YoY (about +1.9%), but net debt is a concern: ~3.68B vs. 2.64B YoY worse, and a sharp QoQ spike (0.97B to 3.68B) indicates balance sheet volatility.

Shareholder Returns

Caution

Total return appears limited: 1Y price change is +0.37% and dividend yield is ~0.42%. No buyback information provided; no strong momentum signal (>20% 1Y) is present.

Analyst Sentiment & Valuation

Positive

Consensus target is 18 vs. current ~16.39, implying ~10% upside. Valuation appears supportive, though earnings momentum is mixed.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Management’s tone is supportive on the core growth engines—especially inpatient rehab—citing a robust pipeline and in-plan performance for critical illness. However, the Q&A pressure centers on the outpatient rehab drawdown and a Q4 earnings miss versus what the quarter’s implied guidance midpoint would suggest. The hard number breakdown shows outpatient weakness largely tied to (1) health insurance expense (~$5M) and (2) variable discount (~$6M), totaling ~$11M, on top of payer mix deterioration (~+$1 per visit impact discussed) and market softness driven by staffing/therapist recruitment. Management also admitted a broader ~ $15M health-insurance impact company-wide in Q4 not anticipated entering the quarter. Versus implied guidance midpoint, management characterized the shortfall as around ~$25M, attributing it to the ~$15M health insurance plus timing issues in inpatient rehab and outpatient softness. Net: growth remains intact, but near-term optics and segment execution risk are clearly the analyst focus.

AI IconGrowth Catalysts

  • Inpatient rehab expansion: added 150 beds in Q4 2025 via openings + acquisitions
  • Inpatient rehab full-year expansion: added 212 rehab beds in 2025 (202 beds from three new hospitals, three acute rehab units, and one neuro-transitional unit; remaining 10 beds from an expansion)
  • Critical illness recovery hospital division: added 10 beds in Savannah, Georgia via acquisition
  • Pipeline for 2026-2027: expected to add 399 beds (166 beds added so far in 2025/YTD)

Business Development

  • New 32-bed hospital with Cleveland Clinic (Q4 rehab expansion)
  • 32-bed acute rehab unit in Orlando, Florida (Q4 rehab expansion)
  • 10-bed expansion at rehab hospital with Riverside Health (Virginia)
  • 76-bed rehabilitation hospital acquisition in partnership with Vibra Healthcare (Southern Kentucky)
  • Opened fifth rehabilitation hospital (January 2026): 45-bed Baylor Scott & White hospital in Temple, Texas
  • Opened CoxHealth 63-bed hospital in Ozark, Missouri
  • Banner Health 58-bed hospital in Tucson, Arizona (JV; 'fourth within the joint venture')
  • Upcoming: 60-bed hospital with AtlantiCare (Southern New Jersey; expected open in 2026)
  • Upcoming: two acute rehab units in Florida and two neuro units scheduled to open in Q2 2026
  • Upcoming: 76-bed rehab hospital in Jersey City (open Q1 2027) and expansion of one Banner rehab hospital by 20 beds

AI IconFinancial Highlights

  • Total revenue: grew >6% YoY in Q4 2025; full-year revenue grew >5%
  • Adjusted EBITDA: $104.7M in Q4 2025 vs $116.0M prior year (-10% YoY)
  • Adjusted EBITDA margin (Q4): outpatient rehab margin fell to 3.4% (from 26.6M prior-year EBITDA; margin down vs prior year not explicitly stated)
  • EPS (continuing operations): $0.16 in Q4 2025 vs diluted loss of $0.19 prior year; adjusted EPS $0.16 vs $0.18 prior year
  • Full-year Adjusted EBITDA: $493.2M with 9% margin vs $510.4M and 9.8% margin in 2024 (margin down 80 bps)
  • Outpatient rehab: net revenue per visit declined to $98 from $102 (-~$4; -~3.9%) driven by Medicare reimbursement reduction, unfavorable payer mix, and increased variable discounts
  • Outpatient rehab: adjusted EBITDA $11.2M vs $26.6M prior year; margin declined to 3.4%
  • Outpatient health insurance expense impact: ~ $5M for the quarter
  • Outpatient variable discount impact: ~ $6M for the quarter
  • Combined outpatient health insurance + variable discount: ~$11M for the quarter
  • Company-wide (Q4): health-insurance-related impact approximated at ~$15M not anticipated entering Q4
  • Q4 EBITDA bridge vs implied midpoint (analyst comment acknowledged): Q4 EBITDA ~$25M short vs $520M midpoint implied (~$25M gap described by management as being 'around $25 million')
  • Management attribution of Q4 shortfall: ~$15M health insurance expense + timing issues in inpatient rehab development + 'softness' in outpatient

AI IconCapital Funding

  • Balance sheet at quarter end: $1.8B debt outstanding; $26.5M cash
  • Debt composition: $1.04B term loans; $100M revolver; $550M 6.25% senior notes due 2032; $155M other debt
  • Net leverage: 3.67x under senior secured credit agreement
  • Revolver availability: $469.1M
  • Operating cash flow (Q4): $64.3M
  • Investing cash flow: used $66.9M (includes $59.1M capex; $9.1M acquisitions/investments)
  • Financing cash flow: used $31.0M (incl. $50.0M net revolver repayments; $38.1M net distributions to noncontrolling interests; $7.8M dividends; $2.6M term-loan repayments; plus $51.3M net proceeds from other debt issuances)
  • Dividend approved: $0.0625 per share payable 03/12/2026; record date 03/02/2026

AI IconStrategy & Ops

  • Inpatient rehab remains the primary growth focus; management expects more rehab hospital space growth, new rehab units, and continued growth in the neuro-transitional center
  • Critical illness and inpatient rehab were described as 'in plan' / 'right in plan or maybe a little better' in Q4
  • IRF/Outpatient softness: management tapered 2H expectations within guidance
  • Labor mix target (critical illness): allocation of 70% full-time / 15% PRN / 15% agency; agency rate 'hovered right around' 15%
  • AI evaluation: piloting AI for back-end billing office processes to improve outpatient collections; potential clinical use cases (virtual sitters, telemetry monitoring)

AI IconMarket Outlook

  • 2026 outlook (company guidance): revenue $5.6B to $5.8B
  • 2026 outlook: Adjusted EBITDA $520M to $540M
  • 2026 outlook: fully diluted EPS $1.22 to $1.32
  • 2026 capex: $200M to $220M
  • Weather: early 2026 weather had no 'material' impact on inpatient divisions; outpatient impacted in some areas/states with recovery 'through the course of the quarter' (timing callout for Q1 2026)
  • Proposed CMS rule timing: management referenced 'proposed rule early summer' with expectations for 10/01/2026 forward (high-cost outlier / LTACH context)
  • CMS TEAM demo: only minor expected impact; spinal fusion surgeries/spinal cord patients could see minor adjustment in impacted partner markets

AI IconRisks & Headwinds

  • Outpatient margin compression: adjusted EBITDA margin down to 3.4% and revenue per visit down due to Medicare reimbursement reduction, payer mix shift, and variable discounts
  • Outpatient headwind quantified: ~ $5M health insurance expense + ~ $6M variable discounts for the quarter; combined ~$11M plus remaining payer mix/market softness
  • Payer mix deterioration: ~ $1 impact on net revenue per visit (per Joanna Gajuk discussion); variable discount ~ $2 impact on net revenue per visit
  • Market softness attributed to staffing constraints (therapist recruitment) and rate evaluation in certain markets
  • Health insurance expense surprise: ~$15M total Select Medical impact in Q4 2025 'did not anticipate coming into the fourth quarter'
  • Inpatient rehab: 'timing issues' with development activities led to underperformance vs expectations/implicit guidance midpoint
  • IRF/inpatient rehab startup losses: margin decline down to 'a little north of 20%' attributed to startup loss; management expects relatively consistent 2026 startup loss (~$15M, a little south of $15M)

Sentiment: MIXED

Note: This summary was synthesized by AI from the SEM Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (SEM)

© 2026 Stock Market Info — Select Medical Holdings Corporation (SEM) Financial Profile